Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system

2014 ◽  
Vol 41 (3) ◽  
pp. 788-796 ◽  
Author(s):  
Juan E. Gutierrez ◽  
Martin Rosenberg ◽  
Michael Duhaney ◽  
Jeffrey A. Simon ◽  
Guenther Brueggenwerth ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Mr Imaging ◽  
Contrast Agent ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Contrast Enhanced ◽  
The Central Nervous System ◽  
Imaging Contrast Agent

MR Imaging of Congenital and Acquired Malformation of the Eye and Orbit

1997 ◽  
Vol 10 (4) ◽  
pp. 423-430 ◽  
Author(s):  
L. Manfrè ◽  
A. Banco ◽  
M. Accardi ◽  
V. D'Antonio ◽  
A. Caronia ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Central Nervous System ◽  
Nervous System ◽  
Magnetic Resonance ◽  
Mr Imaging ◽  
Imaging Modality ◽  
Resonance Imaging ◽  
The Central Nervous System ◽  
Cns Malformations ◽  
Teratogenic Factor

As for all the central nervous system (CNS) defects, the severity of eye malformations is related to the time a teratogenic factor occurs: the earlier the insult, the more serious the eye abnormalities are. Magnetic resonance imaging perfectly depicts most eye defects. Considering that several CNS malformations have been described to occur simultaneously in the case of eye abnormalities, MRI is considered the imaging modality of choice nowadays.

MR imaging of the central nervous system in divers

1991 ◽  
Vol 1 (3) ◽  
pp. 293-299 ◽  
Author(s):  
Peter A. Rinck ◽  
Rasmus Svihus ◽  
Patricia de Francisco
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Mr Imaging ◽  
The Central Nervous System
Sign in / Sign up

Export Citation Format

Share Document